Skip to content

Second cancers and survivorship

TL;DR — The survivor population must be split by heritability. Heritable survivors have a large lifelong subsequent-malignancy burden from germline RB1 predisposition, amplified for some cancers by radiotherapy; non-heritable survivors did not have increased overall incidence in the largest long-term US analysis. Melanoma risk is significantly increased in heritable disease, but the 11.9 SIR is for all subsequent malignancies, not melanoma. Consensus supports skin surveillance and symptom-triggered assessment while acknowledging that routine whole-body imaging has not shown benefit.

Decision-relevant evidence

  • Among 1,128 heritable and 924 non-heritable survivors diagnosed 1914–2006 and followed through 2016, overall subsequent-malignancy SIR was 11.9 (95% CI 10.4–13.5) versus 0.8 (0.5–1.2); SIRs exceeded 80-fold for sarcomas, nasal-cavity tumours and pineoblastoma (Schonfeld 2021, PMID 33473166).

  • Heritable cumulative incidence at 50 years was 33.1% (95% CI 29.0–37.2) for a first and 6.0% (3.8–8.2) for a second subsequent malignancy (PMID 33473166).

  • Melanoma, CNS, oral-cavity and breast SIRs collectively spanned 3.1–17; this is a range across sites, not a melanoma-specific estimate, and risks were not increased for uterus, kidney, lung, bladder, pancreas or other types — a narrower epithelial excess than earlier work suggested (PMID 33473166).

  • A Danish national cohort of 323 patients (133 heritable) reported melanoma SIR 26.78 (95% CI 9.78–58.30) and sarcoma SIR 181.13 (98.94–303.92) in heritable survivors, overall SIR 11.39 (7.37–16.81) with excess absolute risk of 70 cases per 10,000 person-years, versus 1.52 (0.81–2.60) in non-heritable survivors. Cumulative incidence at age 60 was 51% versus 13% (P < .001; HR 5.0, 2.5–10.3) and cumulative second-cancer mortality 34% versus 12% (P = .03). Notably, this cohort found no significant difference in overall second-cancer risk between external radiotherapy, plaque-only and enucleation-only groups, though sarcomas clustered in the irradiated field (Gregersen 2020, PMID 33090227). This estimate belongs to that cohort, not to Schonfeld's.

  • Radiation adds to, rather than replaces, genetic susceptibility. Among 1,604 survivors, subsequent cancers were significantly elevated only in the 961 hereditary patients (190 cancers versus 6.3 expected; RR 30, 95% CI 26–47), 50-year cumulative incidence was 51.0% ± 6.2% hereditary versus 5.0% ± 3.0% non-hereditary, all 114 sarcomas occurred in hereditary patients, and sarcoma risk was evident above 5 Gy rising to 10.7-fold at ≥60 Gy (P < .05) (Wong 1997, PMID 9333268).

  • Sarcoma risk is not uniform in site, age or sex, which is what makes a single surveillance schedule inadequate. In 952 irradiated hereditary survivors, head-and-neck bone sarcoma SIR was 2,213 (95% CI 1,671–2,873) versus 169 (115–239) in body and extremities, and head-and-neck soft-tissue sarcoma 542 (418–692) versus 45.7 (31.1–64.9). In-field tumours appeared from early childhood and continued into adulthood (60-year cumulative incidence 6.8% bone, 9.3% soft tissue), whereas out-of-field bone sarcoma flattened after adolescence (3.5%) and out-of-field soft-tissue sarcoma was rare until age 30 and then rose steeply (6.6% overall, 9.4% in females) (Kleinerman 2019, PMID 31622129).

  • Mortality, not just incidence, separates the two groups: 50-year cumulative mortality from subsequent malignant neoplasms was 25.5% (95% CI 20.8–30.2) in 1,092 hereditary versus 1.0% (0.2–1.8) in 762 non-hereditary survivors, with standardised mortality ratios 35 (30–41) and 2.5 (1.3–4.4). There was no excess mortality from non-neoplastic causes (Yu 2009, PMID 19351917).

  • Second cancers begin appearing within a childhood-length follow-up window. In 3,262 European children followed up to 14 years, 25 subsequent malignant neoplasms gave SIR 8.2 overall, 5 for haematological tumours and 29 for bone and soft-tissue sarcomas, at mean ages of 1.3–8.9 years by site (Virgili 2024, PMID 39388193).

  • Osteosarcoma is the commonest solid second malignancy and is treatable. In 857 registered retinoblastoma patients, 10 (1.1%) developed osteosarcoma at a median of 11.2 years; four were radiation-related and six arose in an extremity, and three of four extremity cases treated with wide resection plus high-dose methotrexate-based chemotherapy were good responders and survived disease-free at median 17.3 years (Fujiwara 2015, PMID 26438540). An older single-centre cohort of 172 children found second malignancies in six (3.5%), all in bilateral or asynchronous bilateral disease, all irradiated, at 125–194 months after radiotherapy of 32–45.76 Gy, with four of six dying of the second cancer and an estimated 20-year risk of 24% (Fontanesi 1995, PMID 8556278).

  • Adult consensus found no evidence supporting routine imaging of asymptomatic survivors, while endorsing skin examination for melanoma and prompt assessment of head-and-neck signs and symptoms; the panel screened 139 articles and abstracted 37, and noted that surveillance practice varies widely by centre with no recommendations previously in place (Tonorezos 2020, PMID 32422154).

  • Subsequent malignancies and trilateral disease, not the eye tumour, are the leading cause of death in heritable survivors in high-income settings, and treatment choice modifies that risk on top of the germline predisposition (Fabius 2021, PMID 33801943).

  • The non-heritable group must not inherit the heritable group's risk profile in communication or in follow-up design: their overall subsequent-cancer SIR was 0.8 (0.5–1.2) in the largest cohort (PMID 33473166) and 1.52 (0.81–2.60) in the Danish cohort (PMID 33090227) — neither significantly above the general population.

Clinical and research frame

Domain Operational meaning Evidence boundary
Heritable survivor High lifelong SMN burden Genetic predisposition ± treatment
Non-heritable survivor No overall increase in Schonfeld cohort Do not merge with heritable group
Radiation field Very high head/neck sarcoma risk Dose and era matter
Melanoma Significantly increased in heritable disease Cross-link melanoma; do not merge ocular entities
Routine imaging Benefit unproven Potential radiation, false-positive and burden harms

Interpretation rules

  • Keep the child-level endpoints of survival and metastasis separate from the eye-level endpoint of globe salvage.

  • Report initial stage, laterality, heritability, prior treatment and follow-up; otherwise comparisons are not transportable.

  • A retrospective eye series estimates performance in selected eyes; it does not establish superiority over another route.

  • Absence of metastasis in a small series is a safety observation, not proof that risk is zero.

  • Treatment-era effects matter because external-beam radiotherapy, systemic chemotherapy, IAC and intravitreal therapy create different late-risk profiles.

  • Income stratum and access are effect modifiers, not background descriptors (Global Retinoblastoma Study Group 2022, PMID 35839812).

Evidence register

The following records were each retrieved live from PubMed E-utilities on 2026-09-01 and re-fetched live during the independent audit on the same date. Every identifier below resolved, and its author, year, journal and title matched the citation as written. Inclusion records the evidence base for this page; a register entry asserts that the record exists and is on topic, not that it supports a specific effect estimate.

PMID Year Study or review Role in this page
33473166 2021 Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors. Topic-resolved source (Schonfeld 2021, PMID 33473166)
33090227 2020 Incidence and Mortality of Second Primary Cancers in Danish Patients With Retinoblastoma, 1943-2013. Topic-resolved source (Gregersen 2020, PMID 33090227)
9333268 1997 Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. Topic-resolved source (Wong 1997, PMID 9333268)
32422154 2020 Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma. Topic-resolved source (Tonorezos 2020, PMID 32422154)
35839812 2022 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Topic-resolved source (Global 2022, PMID 35839812)
20687510 2010 Retinoblastoma. Topic-resolved source (Lohmann 2010, PMID 20687510)
25473349 2014 Retinoblastoma: An overview. Topic-resolved source (Pandey 2014, PMID 25473349)
39388193 2024 Survival and Health Care Burden of Children With Retinoblastoma in Europe. Topic-resolved source (Virgili 2024, PMID 39388193)
10761080 1998 Retinoblastoma. Topic-resolved source (Margo 1998, PMID 10761080)
28069617 2017 Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma. Topic-resolved source (Vasalaki 2017, PMID 28069617)
34861419 2022 Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma. Topic-resolved source (Chai 2022, PMID 34861419)
9862317 1998 Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. Topic-resolved source (Murray 1998, PMID 9862317)
26438540 2015 Second primary osteosarcomas in patients with retinoblastoma. Topic-resolved source (Fujiwara 2015, PMID 26438540)
27124644 2017 Mesenchymal stromal cells having inactivated RB1 survive following low irradiation and accumulate damaged DNA: Hints for side effects following radiotherapy. Topic-resolved source (Alessio 2017, PMID 27124644)
8556278 1995 Second malignant neoplasms in children with retinoblastoma: the St. Jude Children's Research Hospital experience. Topic-resolved source (Fontanesi 1995, PMID 8556278)
38804799 2024 Retinoblastoma - A comprehensive review, update and recent advances. Topic-resolved source (Nag 2024, PMID 38804799)
27189421 2015 Retinoblastoma. Topic-resolved source (Dimaras 2015, PMID 27189421)
37667345 2023 Retinoblastoma: present scenario and future challenges. Topic-resolved source (Byroju 2023, PMID 37667345)
33120616 2020 Modern treatment of retinoblastoma: A 2020 review. Topic-resolved source (Ancona-Lezama 2020, PMID 33120616)
38615905 2024 Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Topic-resolved source (Zhou 2024, PMID 38615905)
28620731 2017 Retinoblastoma. Topic-resolved source (Rao 2017, PMID 28620731)
34987197 2023 Retinoblastoma and vision. Topic-resolved source (Warda 2023, PMID 34987197)
25435120 2015 Retinoblastoma. Topic-resolved source (Rodriguez-Galindo 2015, PMID 25435120)
16570739 2006 Retinoblastoma. Topic-resolved source (Melamud 2006, PMID 16570739)
24100372 2013 Retinoblastoma. Topic-resolved source (Villegas 2013, PMID 24100372)
22414599 2012 Retinoblastoma. Topic-resolved source (Dimaras 2012, PMID 22414599)
16572402 2007 Trilateral retinoblastoma. Topic-resolved source (Antoneli 2007, PMID 16572402)
16934146 2006 Retinoblastoma. Topic-resolved source (Aerts 2006, PMID 16934146)
28558178 2017 Retinoblastoma: Update on Current Management. Topic-resolved source (Cassoux 2017, PMID 28558178)
8199450 1993 Retinoblastoma. Topic-resolved source (Abramson 1993, PMID 8199450)
22337189 2012 Retinoblastoma. Topic-resolved source (Mehta 2012, PMID 22337189)
27609158 2016 Adult onset retinoblastoma. Topic-resolved source (Sengupta 2016, PMID 27609158)
2059954 1991 Retinoblastoma. Topic-resolved source (Servodidio 1991, PMID 2059954)
30385881 2019 Retinoblastoma in Asia. Topic-resolved source (Jain 2019, PMID 30385881)
33583507 2021 Neonatal Retinoblastoma. Topic-resolved source (Lin 2021, PMID 33583507)
26023180 2016 Retinoblastoma. Topic-resolved source (Ortiz 2016, PMID 26023180)
41002743 2025 A Comprehensive Review of the Epidemiology, Pathophysiology, Risk Factors, and Treatment Strategies for Retinoblastoma. Topic-resolved source (Kumari 2025, PMID 41002743)
38492167 2024 Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Topic-resolved source (Singh 2024, PMID 38492167)
34226484 2021 Retinoblastoma: A Major Review. Topic-resolved source (Roy 2021, PMID 34226484)
34210807 2021 Update on the Treatment of Retinoblastoma. Topic-resolved source (Manrique 2021, PMID 34210807)
31622129 2019 Bone and Soft-Tissue Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Treated With Radiation. Added by audit 2026-09-01 (Kleinerman 2019, PMID 31622129)
19351917 2009 Cause-specific mortality in long-term survivors of retinoblastoma. Added by audit 2026-09-01 (Yu 2009, PMID 19351917)
33801943 2021 Subsequent Malignant Neoplasms in Retinoblastoma Survivors. Added by audit 2026-09-01 (Fabius 2021, PMID 33801943)

Source chronology

Era marker PMID What the record contributes
1991 2059954 Retinoblastoma. (Servodidio 1991, PMID 2059954)
1993 8199450 Retinoblastoma. (Abramson 1993, PMID 8199450)
1995 8556278 Second malignant neoplasms in children with retinoblastoma: the St. Jude Children's Research Hospital experience. (Fontanesi 1995, PMID 8556278)
1997 9333268 Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. (Wong 1997, PMID 9333268)
1998 9862317 Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. (Murray 1998, PMID 9862317)
1998 10761080 Retinoblastoma. (Margo 1998, PMID 10761080)
2006 16570739 Retinoblastoma. (Melamud 2006, PMID 16570739)
2006 16934146 Retinoblastoma. (Aerts 2006, PMID 16934146)
2007 16572402 Trilateral retinoblastoma. (Antoneli 2007, PMID 16572402)
2010 20687510 Retinoblastoma. (Lohmann 2010, PMID 20687510)
2012 22337189 Retinoblastoma. (Mehta 2012, PMID 22337189)
2012 22414599 Retinoblastoma. (Dimaras 2012, PMID 22414599)
2013 24100372 Retinoblastoma. (Villegas 2013, PMID 24100372)
2014 25473349 Retinoblastoma: An overview. (Pandey 2014, PMID 25473349)
2015 25435120 Retinoblastoma. (Rodriguez-Galindo 2015, PMID 25435120)

Evidence limitations

  • Most intraocular treatment evidence is observational, single-centre and reported per eye; bilateral eyes within one child are statistically correlated.

  • Classification and treatment changed over time, producing stage migration and confounding by indication.

  • Rare metastatic and late-effect outcomes require multinational cohorts and decades of follow-up.

  • Verification is abstract-level. Every claim on this page was checked against the abstract of the record it cites during the independent audit on 2026-09-01; where an abstract could not support a claim, the claim was removed or restated as an explicit limit. Claims requiring full text beyond the abstract are not made here.

Open questions

  • Has SMN incidence fallen after displacement of external-beam radiotherapy? The current evidence register defines the design space but does not close the question.

  • Can targeted surveillance demonstrate mortality benefit? The current evidence register defines the design space but does not close the question.

  • Which modern exposures interact with germline RB1 risk? The current evidence register defines the design space but does not close the question.

References

  1. Schonfeld SJ, et al. Long-term risk of subsequent cancer incidence among hereditary and nonhereditary retinoblastoma survivors. British journal of cancer. 2021;124:1312-1319. PMID 33473166
  2. Gregersen PA, et al. Incidence and Mortality of Second Primary Cancers in Danish Patients With Retinoblastoma, 1943-2013. JAMA network open. 2020;3:e2022126. PMID 33090227
  3. Wong FL, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278:1262-7. PMID 9333268
  4. Tonorezos ES, et al. Recommendations for Long-Term Follow-up of Adults with Heritable Retinoblastoma. Ophthalmology. 2020;127:1549-1557. PMID 32422154
  5. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet. Global health. 2022;10:e1128-e1140. PMID 35839812
  6. Lohmann D. Retinoblastoma. Advances in experimental medicine and biology. 2010;685:220-7. PMID 20687510
  7. Pandey AN. Retinoblastoma: An overview. Saudi journal of ophthalmology : official journal of the Saudi Ophthalmological Society. 2014;28:310-5. PMID 25473349
  8. Virgili G, et al. Survival and Health Care Burden of Children With Retinoblastoma in Europe. JAMA ophthalmology. 2024;142:1062-70. PMID 39388193
  9. Margo CE, et al. Retinoblastoma. Cancer control : journal of the Moffitt Cancer Center. 1998;5:310-316. PMID 10761080
  10. Vasalaki M, et al. Ocular oncology: advances in retinoblastoma, uveal melanoma and conjunctival melanoma. British medical bulletin. 2017;121:107-119. PMID 28069617
  11. Chai P, et al. Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma. Progress in retinal and eye research. 2022;89:101030. PMID 34861419
  12. Murray T. Cancer incidence after retinoblastoma: radiation dose and sarcoma risk. Survey of ophthalmology. 1998;43:288-9. PMID 9862317
  13. Fujiwara T, et al. Second primary osteosarcomas in patients with retinoblastoma. Japanese journal of clinical oncology. 2015;45:1139-45. PMID 26438540
  14. Alessio N, et al. Mesenchymal stromal cells having inactivated RB1 survive following low irradiation and accumulate damaged DNA: Hints for side effects following radiotherapy. Cell cycle (Georgetown, Tex.). 2017;16:251-258. PMID 27124644
  15. Fontanesi J, et al. Second malignant neoplasms in children with retinoblastoma: the St. Jude Children's Research Hospital experience. Ophthalmic genetics. 1995;16:105-8. PMID 8556278
  16. Nag A, et al. Retinoblastoma - A comprehensive review, update and recent advances. Indian journal of ophthalmology. 2024;72:778-788. PMID 38804799
  17. Dimaras H, et al. Retinoblastoma. Nature reviews. Disease primers. 2015;1:15021. PMID 27189421
  18. Byroju VV, et al. Retinoblastoma: present scenario and future challenges. Cell communication and signaling : CCS. 2023;21:226. PMID 37667345
  19. Ancona-Lezama D, et al. Modern treatment of retinoblastoma: A 2020 review. Indian journal of ophthalmology. 2020;68:2356-2365. PMID 33120616
  20. Zhou M, et al. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2024;13:100058. PMID 38615905
  21. Rao R, et al. Retinoblastoma. Indian journal of pediatrics. 2017;84:937-944. PMID 28620731
  22. Warda O, et al. Retinoblastoma and vision. Eye (London, England). 2023;37:797-808. PMID 34987197
  23. Rodriguez-Galindo C, et al. Retinoblastoma. Pediatric clinics of North America. 2015;62:201-23. PMID 25435120
  24. Melamud A, et al. Retinoblastoma. American family physician. 2006;73:1039-44. PMID 16570739
  25. Villegas VM, et al. Retinoblastoma. Current opinion in ophthalmology. 2013;24:581-8. PMID 24100372
  26. Dimaras H, et al. Retinoblastoma. Lancet (London, England). 2012;379:1436-46. PMID 22414599
  27. Antoneli CB, et al. Trilateral retinoblastoma. Pediatric blood & cancer. 2007;48:306-10. PMID 16572402
  28. Aerts I, et al. Retinoblastoma. Orphanet journal of rare diseases. 2006;1:31. PMID 16934146
  29. Cassoux N, et al. Retinoblastoma: Update on Current Management. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2017;6:290-295. PMID 28558178
  30. Abramson DH, et al. Retinoblastoma. Optometry clinics : the official publication of the Prentice Society. 1993;3:49-61. PMID 8199450
  31. Mehta M, et al. Retinoblastoma. Singapore medical journal. 2012;53:128-35; quiz 136. PMID 22337189
  32. Sengupta S, et al. Adult onset retinoblastoma. Indian journal of ophthalmology. 2016;64:485-91. PMID 27609158
  33. Servodidio CA, et al. Retinoblastoma. Cancer nursing. 1991;14:117-23. PMID 2059954
  34. Jain M, et al. Retinoblastoma in Asia. Eye (London, England). 2019;33:87-96. PMID 30385881
  35. Lin FY, et al. Neonatal Retinoblastoma. Clinics in perinatology. 2021;48:53-70. PMID 33583507
  36. Ortiz MV, et al. Retinoblastoma. Journal of child neurology. 2016;31:227-36. PMID 26023180
  37. Kumari A, et al. A Comprehensive Review of the Epidemiology, Pathophysiology, Risk Factors, and Treatment Strategies for Retinoblastoma. Diseases (Basel, Switzerland). 2025;13. PMID 41002743
  38. Singh L, et al. Epidemiology, Diagnosis and Genetics of Retinoblastoma: ICMR Consensus Guidelines. Indian journal of pediatrics. 2024;91:1147-1156. PMID 38492167
  39. Roy SR, et al. Retinoblastoma: A Major Review. Mymensingh medical journal : MMJ. 2021;30:881-895. PMID 34226484
  40. Manrique M, et al. Update on the Treatment of Retinoblastoma. NeoReviews. 2021;22:e423-e437. PMID 34210807
  41. Kleinerman RA, et al. Bone and Soft-Tissue Sarcoma Risk in Long-Term Survivors of Hereditary Retinoblastoma Treated With Radiation. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37:3436-3445. PMID 31622129
  42. Yu CL, et al. Cause-specific mortality in long-term survivors of retinoblastoma. Journal of the National Cancer Institute. 2009;101:581-91. PMID 19351917
  43. Fabius AWM, et al. Subsequent Malignant Neoplasms in Retinoblastoma Survivors. Cancers. 2021;13. PMID 33801943